TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brainstorm Cell Therapeutics ( (BCLI) ) just unveiled an update.
On October 31, 2025, Brainstorm Cell Therapeutics entered into a securities purchase agreement with Vanquish Funding Group, issuing a promissory note for $182,400 and receiving $155,000 after fees. This agreement allows for potential additional financing of up to $2 million over the next year, impacting the company’s financial strategy and providing opportunities for further development.
The most recent analyst rating on (BCLI) stock is a Hold with a $6.60 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.
Spark’s Take on BCLI Stock
According to Spark, TipRanks’ AI Analyst, BCLI is a Underperform.
Brainstorm Cell Therapeutics’ stock score is significantly impacted by its financial performance challenges, including ongoing losses and negative cash flows. While there are strategic advancements and partnerships aimed at derisking the regulatory pathway, the company’s valuation and technical indicators reflect a bearish outlook. Investors should be cautious due to financial constraints and skepticism regarding the efficacy of its lead treatment, NurOwn.
To see Spark’s full report on BCLI stock, click here.
More about Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. operates in the biotechnology industry, focusing on the development of innovative cellular therapies for neurodegenerative diseases.
Average Trading Volume: 25,067
Technical Sentiment Signal: Sell
Current Market Cap: $6.93M
For detailed information about BCLI stock, go to TipRanks’ Stock Analysis page.